Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business updat ...

Negative P/E ratio of -29.54 indicates current unprofitability.Low debt-to-equity ratio of 0.12 suggests a conservative approach to debt.High price-to-sales ratio of 183.24 reflects significant market expectations for future growth.ACLX (NASDAQ:ACLX), is currently navigating through financial challenges, highlighted by its negative price-to-earnings (P/E) ratio of -29.54, signaling that the company is not profitable at this time. Despite this, ACLX exhibits a low debt-to-equity ratio of 0.12, indicating a c ...

Cory Kasimov from Evercore ISI set a price target of $115 for NASDAQ:ACLX, indicating a slight 1.04% difference from its current trading price.Gilead Sciences plans to acquire Arcellx for up to $7.8 billion, aiming to enhance its cancer treatment portfolio.The acquisition news has led to a significant increase in ACLX's stock price, soaring 77.8% in premarket trading and reflecting a 77.50% rise to $113.80.Arcellx, listed on the NASDAQ:ACLX, is a biotechnology company focused on developing innovative cancer ...

Core Viewpoint - Arcellx, Inc. is experiencing significant market activity due to Gilead Sciences' planned acquisition, which is valued at $7.8 billion, marking a pivotal moment for the company and its stock performance [2][4]. Group 1: Stock Performance - Arcellx's stock surged approximately 80% in premarket trading following the acquisition announcement, with the current stock price at $113.81, reflecting a 77.52% increase and a $49.70 change [2]. - The stock has fluctuated between $113.80 and $114.26, marking its highest price over the past year, compared to a previous low of $47.86, indicating substantial growth [3]. Group 2: Acquisition Details - Gilead Sciences plans to acquire Arcellx in an all-cash deal valued at $7.8 billion, which is Gilead's largest acquisition since 2020, aimed at enhancing its cancer treatment portfolio [2]. - The acquisition involves acquiring the remaining shares of Arcellx, further solidifying Gilead's position in the biotech sector [4]. Group 3: Market Capitalization and Trading Volume - Arcellx's market capitalization is approximately $6.58 billion, with a trading volume of around 18.59 million shares, reflecting strong investor interest following the acquisition news [4].

Fed Governor Christopher Waller said his decision on whether to support an interest rate cut at the March FOMC meeting will hinge on labor market data for February.The US Feb Dallas Fed manufacturing outlook level of general business activity survey rose +1.4 to a 7-month high of 0.2, stronger than expectations of -0.5.The US Jan Chicago Fed National Activity Index rose +0.39 to a 9-month high of 0.18, stronger than expectations of 0.01.Geopolitical risks are also negative for stocks. US-Iran nuclear talks ...

Group 1: Kraig Biocraft Laboratories - Kraig Biocraft Laboratories' recombinant spider silk technology has gained significant visibility by being featured on the cover of National Geographic's March 2026 issue, which could lead to increased investor interest [2][4] - The company is set to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, aiming for a production target of up to 10 metric tons of cocoons per month starting in March 2026 [5] - Scientific validation published in the Proceedings of the National Academy of Sciences confirms that Kraig's fibers are tougher than conventional silk and comparable to native spider dragline silk [5] - If successful, Kraig could become the second company to achieve sustained commercial production from a transgenic animal platform, a milestone previously associated with ATryn [6] - Investors are closely monitoring for initial deliveries to global brand partners in luxury fashion and performance sportswear, which could transition Kraig from a research-focused entity to a specialty materials platform [8] Group 2: Gilead Sciences and Arcellx - Gilead Sciences has announced a definitive agreement to acquire Arcellx for $115 per share in cash, plus a $5 contingent value right, representing an implied equity value of approximately $7.8 billion [9] - The acquisition provides Gilead with full control of anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma, with the FDA accepting the BLA and a PDUFA action date set for December 23, 2026 [10] - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in enhancing Gilead's oncology and inflammation capabilities [11] Group 3: ImmunityBio - ImmunityBio reported approximately $113 million in net product revenue for ANKTIVA in 2025, reflecting a 700% year-over-year growth [13] - The company also experienced a 750% increase in unit sales volume and expanded regulatory authorization across 33 countries [13] - ImmunityBio is positioning ANKTIVA as a backbone immunotherapy platform with ongoing randomized trials and long-term patent protection extending beyond 2035 [15] Group 4: Getty Images and Shutterstock - Getty Images and Shutterstock received unconditional antitrust clearance from the U.S. Department of Justice for their proposed merger, which aims to strengthen their financial foundation and competitive positioning in the visual content market [16][17]

Core Viewpoint - Arcellx's stock surged approximately 80% following Gilead Sciences' announcement to acquire the cancer-therapy developer for $7.8 billion in an all-cash deal, with a definitive buyout price set at $115 per share [1]. Deal Structure - Gilead will pay $115 per share in cash, plus a contingent value right (CVR) worth an additional $5 per share if Arcellx's lead therapy, anito-cel, achieves at least $6 billion in cumulative global net sales by the end of 2029 [1]. - The total offer represents a premium of about 87% over Arcellx's previous closing price, prompting immediate trading activity towards the buyout price [1]. - The transaction is structured as a tender offer followed by a second-step merger, already approved by both companies' boards [1]. Strategic Importance - Gilead is acquiring anitocabtagene autoleucel (anito-cel), a CAR-T therapy for relapsed or refractory multiple myeloma, which presents a significant commercial opportunity despite intense competition from established products like Johnson & Johnson's Carvykti [1]. - Analysts have previously noted supportive data for anito-cel's potential, with comparisons to Carvykti as the datasets have matured [1]. - The FDA is expected to make a decision on anito-cel by December 23, 2026, which positions the acquisition within a near-launch timeframe rather than a distant research phase [1]. Historical Context - Gilead and Arcellx have collaborated in cell therapy since 2022, making this acquisition a consolidation of a program that Gilead is already familiar with [1].

Hello and welcome to Asking for a Trend. I'm Josh Lipton and for the next half hour we are breaking down the trends of today that'll move stocks tomorrow. There's a lot to keep track of, so we're focusing on what you need to know to get ahead of the curve.Here are some of the trends we're going to be diving into. It was a mixed day on Wall Street. The S&P 500 come under pressure as investors wait on key economic data later this week.The crypto winner rippling across the industry and we're seeing how it affe ...

Market Overview - Bitcoin has dropped to $60,000 from a record high of $124,000, indicating a downward trend in market froth [1] - Share markets, including the ASX 200 index, have seen significant declines, with a 2% drop on Friday [2] - A local market wipeout of nearly $65 billion occurred, marking the largest fall since April of the previous year, with all sectors closing lower [3] Sector Performance - The ASX technology sector fell by 12.6% for the week, driven by concerns over AI investments and their potential returns [6] - Major tech companies like Amazon saw an 11% drop in shares due to high capital expenditure plans, impacting technology stocks in Australia [7] - Real estate stocks weakened, with Goodman Group falling 6.1% and REA Group down 7.8% after disappointing profit results [11] Commodity and Mining Sector - Gold and silver prices have weakened, with silver experiencing a 2% increase after an 18% fall in the previous session [8] - Major mining companies like BHP, South32, and Newmont saw declines in their share prices, with BHP down 3.1% [9] - Rio Tinto shares remained flat after ending merger talks with Glencore [10] Upcoming Economic Indicators - The focus will shift to household spending data expected to show some weakening, while new home loan data is anticipated to increase by around 6% [14] - US jobs figures are expected to show an addition of around 50,000 jobs, with the unemployment rate steady at 4.4% [15]

Core Insights - Ligand Pharmaceuticals will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with CEO Todd Davis and CFO Tavo Espinoza attending a fireside chat [1] - The company will also host one-on-one meetings with investors during the conference, encouraging interested parties to contact their Oppenheimer representative for arrangements [2] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [3] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand's strategy includes funding mid- to late-stage drug development programs in exchange for economic rights, purchasing royalty rights, and licensing technology to assist partners in drug discovery and development [3] - The company operates two royalty-generating technology platforms: Captisol®, which enhances drug solubility and stability, and NITRICIL™, which allows for tunable dosing and adjustable drug release profiles [3] - Ligand has established partnerships with leading pharmaceutical companies such as Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]